Press Releases
Clinical Trials
Catalent Partners with Humanigen to Support FDA-Approved Phase 3 Lenzilumab Study for COVID-19
Catalent, a global leader in clinical supply services, welcomed the news by Humanigen, Inc., that it has dosed the first COVID-19 patient in its previously announced Phase 3 study for lenzilumab, the company’s proprietary Humaneered® anti-human granulocyte macrophage-colony stimulating...
Clinical Trials
Glenmark initiates Phase 3 clinical trials on antiviral Favipiravir for COVID-19 patients in India
Glenmark Pharmaceuticals, a research-led, integrated global pharmaceutical company has initiated Phase 3 clinical trials in India on Antiviral tablet Favipiravir, for which it received approval from India’s drug regulator DCGI in late April. Glenmark is the first company in...
Press Releases
Digital Science reports that just 10% of global research output relates to the UN’s Sustainable Development Goals
Digital Science, a leading technology company serving emergent needs across the research sector, has released a report highlighting the growth in research around the UN’s Sustainable Development Goals (SDGs).
The report Contextualizing Sustainable Development Research, which was produced by Digital...
Press Releases
Pfizer and BioNTech Dose First Participants in the U.S. as Part of Global COVID-19 mRNA Vaccine Development Program
Pfizer Inc. and BioNTech SE announced that the first participants have been dosed in the U.S. in the Phase 1/2 clinical trial for the BNT162 vaccine program to prevent COVID-19. The trial is part of a global development program,...
Press Releases
Quotient Sciences and CytoAgents Accelerate Potential Treatment for COVID-19 Cytokine Storm
A collaboration to accelerate the development of a lead COVID-19 drug candidate into human clinical trials was announced by Quotient Sciences, a leading provider of innovative drug development and manufacturing solutions, and CytoAgents, Inc., a privately held biotechnology company...
Press Releases
CEPI announces COVID-19 vaccine development partnership with Clover Biopharmaceuticals Australian Subsidiary
CEPI, the Coalition for Epidemic Preparedness Innovations, announced a ninth worldwide collaboration to develop a COVID-19 vaccine. CEPI will invest an initial US$3.5 million in a partnering agreement with Clover Biopharmaceuticals AUS Pty Ltd a wholly-owned subsidiary of Sichuan...
Press Releases
INOVIO Expands Manufacturing of COVID-19 DNAVaccine INO-4800 With New Funding from CEPI
INOVIO announced it has entered into an agreement to expand its manufacturing partnership with the German contract manufacturer Richter-Helm BioLogics GmbH & Co. KG, to support large-scale manufacturing of INOVIO's investigational DNA vaccine INO-4800, which currently is in Phase...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read